Imbian Lab Unified test for determining influenza and COVID-19

Main article: Tests for coronavirus COVID-19

2022: Development of a single test to determine influenza and COVID-19

The SEZ "Technopolice Moscow" has developed a single test to determine the disease.

The development will help determine whether a patient has influenza or COVID-19 in one test. It will be possible to buy an express system in the city's pharmacies at the end of June 2022. This was announced on May 25, 2022 by Technopolice of os the words of the head of the Department of Investment and Industrial Policy, which is part of the Complex of Economic Policy and Property and Land Relations of the capital, Vladislav Ovchinsky.

A company from the SEZ of Moscow has created a test system that, according to the results of a single analysis, gives an answer whether influenza or Covid-19 is present in the body. This solution makes it cheaper and easier to diagnose, which is fundamentally important for choosing the right treatment. The test system will be launched into mass production in June 2022, the first batch will be 100 thousand units. It will be available in laboratories and pharmacies in Moscow, and then in the regions of Russia, - said Vladislav Ovchinsky.

The test system looks like a standard pharmacy express kit for detecting influenza - a cassette the size of a thermometer with indicators of influenza A and B, as well as a mark about Covid-19. Nasopharyngeal swabs are used as analysis samples. Place the test material in a vial containing a special solution. Further, a drop of solution is applied to the cassette window, after which a corresponding strip appears on the test scale in the presence of infection.

It took about a year and a half to develop the test itself and invested about 5 million, "said Veronika Osipova, general director of the Imbian Lab development company. - We made sure that the system recognizes influenza A and B, as well as all known strains of Covid-19, including Omicron and Stels. If its next strain appears, we will conduct additional clinical trials. The development will make it possible to fill the need for Russian diagnostic systems, which is growing amid the withdrawal of foreign suppliers from the market. At the same time, its main quality is accessibility for a patient who can halve his costs for diagnostics.

The average retail price of a rapid test for Covid-19, which recognizes the presence of a virus antigen, is within 500 rubles. An express test that detects influenza A and B costs up to a thousand rubles. Accordingly, a person spends an average of one and a half thousand rubles on research. This product, as the developer promises, will cost the buyer within 700 rubles.